Mounjaro vs Zepbound
A side-by-side look at Mounjaro and Zepbound, two prescription medications advertised on TV. Informational only — not medical advice.
| US Mounjaro | US Zepbound | |
|---|---|---|
| Generic name | tirzepatide | tirzepatide |
| Drug class | GIP/GLP-1 Receptor Agonist | GIP/GLP-1 Receptor Agonist |
| Treats | Type 2 diabetes | Chronic weight management, obstructive sleep apnea |
| Category | Diabetes | Weight Management |
| Manufacturer | Eli Lilly | Eli Lilly |
| Year approved | 2022 | 2023 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $350M | $300M |
| Common side effects | Nausea, Diarrhea, Decreased appetite, Vomiting | Nausea, Diarrhea, Vomiting, Constipation |
Frequently asked questions
Is Mounjaro or Zepbound better?
Neither is universally "better." Mounjaro (tirzepatide) is used for type 2 diabetes, while Zepbound (tirzepatide) is used for chronic weight management, obstructive sleep apnea, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Mounjaro and Zepbound?
Mounjaro is a GIP/GLP-1 Receptor Agonist made by Eli Lilly, while Zepbound is a GIP/GLP-1 Receptor Agonist made by Eli Lilly. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Mounjaro has the larger estimated TV advertising budget of the two.